Enlivex Therapeutics Board of Directors Approves Purchase of $1 Million in BTC as Reserve Assets

Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a U.S. listed company, announced yesterday that the company's board of directors approved the purchase of up to $1 million in Bitcoin as part of its cash management strategy. Enlivex CEO Oren Hershkovitz said that with the growing demand for Bitcoin and its increasing acceptance as a recognized medium of exchange, the company needs to reserve such strong and diversified assets. And with the recent approval of Bitcoin ETFs and the increasing support of institutional investors, Bitcoin can provide companies with potential functional value storage and inflation hedges for standard currencies. It is reported that Enlivex is a clinical-stage macrophage reprogramming immunotherapy company. (Globenewswire)